

**DAVID A. SUGAR, MD
CURRICULUM VITAE**

Personal:

Birthplace: Chicago, IL

Birthdate: September 2, 1964

Marital Status: Married

Home Address: 7314 Point of Rocks Rd.
Sarasota, FL 34242

Home Phone: 941.349.9605

Business Address: 1921 Waldemere Street, Suite 610
Sarasota, FL 34239

Business Phone: 941.556.6900

Business Fax: 941.556.6920

Undergraduate Education:

| | | |
|------------------------------------|--|------------------|
| University of South Florida | | 1984-1988 |
| Degree: | B.S. in Microbiology | 1988 |
| Honors: | Outstanding College Students of America Golden Key National Honor Society Phi Kappa Phi Honor Society Themis Honor Society Dean's List | |
| Research | "Genetic Transformation and the Acquisition Of Antibiotic Resistance in Vibrio Parahaemolyticus" Advisor/Mentor: Gregory J. Stewart, Ph.D., Department of Biology, U.S.F. | 1988 |

Medical Education:

| | | |
|---|---|-----------|
| University of South Florida College of Medicine | | 1988-1992 |
| Degree: | M.D. | 1992 |
| Honors: | AOA Membership | 1991 |
| | Senior Honor Surgery Program | 1991 |
| | Research Grant, American Heart Association | 1989 |
| | Ambrose Pare Award/Outstanding Student In Surgery | 1992 |
| Research: | “Growth Patterns of Fetal and Neonatal Myocytes in Rats.” Under a grant from The American Heart Association. This was subsequently incorporated in a four-year NIH project studying myocyte growth patterns and morphology. Advisor: Martin Gerdes, Ph.D., USF – COM | 1988-1989 |
| Presentations: | “Prediction of Postoperative Infection in Revision Hip Surgery.” Presented at the AAOS Annual Meeting New Orleans, Louisiana, February 1990 as a poster exhibit | 1990 |
| | “Myocyte Growth Patterns in Fetal and Neonatal Rats.” Presented at the University of South Florida College of Medicine Student Research Symposium, August 1989 | 1989 |

- Publications:**
- “Methanol Intoxication: How to Help Patients Who Have Been Exposed to Toxic Solvents.”**
Rubens J. Pamies, M.D., David A. Sugar, M.D.
Luis Rives, M.D., Arthur H. Herold, M.D.
Post Graduate Medicine
June 1993, Vol. 93, No. 8
- “Methanol Intoxication: Case Report.”**
Rubens J. Pamies, M.D., David A. Sugar, M.D.
Luis Rives, M.D., Arthur H. Herold, M.D.
The Journal of the Florida Medical Association
Inc., July 1993, Vol 80, No. 7

Post Graduate Education:

- | | | |
|--------------------|--|------------------|
| Internship: | General Surgery University of South Florida Department of Surgery | 1992-1993 |
| Residency: | Tampa Orthopaedic Program Orthopaedic Resident | 1993-1994 |
| | Rush Presbyterian – St. Luke’s Medical Center Orthopaedic Resident | 1994-1997 |
| | Chief Resident Shriner’s Hospital for Crippled Children Chicago Unit | 1995 |
| | Administrative Chief Resident Rush Presbyterian – St. Luke’s Medical Center | 1996 |
| | Residency Selection Committee Member | 1996-1997 |

- Presentations:** “Improved Sitting Balance in Patients with Duchenne Muscular Dystrophy Following Spinal Fusion and Instrumentation.” 1997
Presented at The Congress of the European Federation of National Associations of Orthopaedics and Traumatology.
Barcelona, Spain – April 1997
- Publications:** “Dynamic Knee Loads During Gait Predict Proximal Tibial Bone Distribution.”
Accepted for publication in Journal of Biomechanics
- Awards:** Jorge O. Galante Award of Excellence in Orthopedic Research. Given at the Rush Presbyterian – St. Luke’s Medical Center, Department of Orthopaedic’s Annual Thesis Day 1997
- Board Certification:** American Board of Orthopedic Surgery
Board Certification July 13, 2000
Board Re-Certification January 1, 2012

Work History:

- Nov. 2009 - Present** Sugar Orthopaedics
1921 Waldemere Street, Suite 610
Sarasota, FL 34239
Orthopaedic Surgeon
- Jan. 1998 - Oct. 2009** Sarasota Orthopedic Associates
2750 Bahia Vista Street, Suite 100
Sarasota, FL 34239
Orthopaedic Surgeon
- Aug. 1997 - Dec. 1997** Matthews Orthopedic Clinic
501 S. Lincoln, Suite 24
Clearwater, FL 33756
Orthopaedic Surgeon

David A. Sugar, M.D.
Page Five

Committee/Administrative Position

| | |
|--------------|--|
| 2018-Present | Chairman Surgical QI Committee |
| 1999-Present | Member Surgical Peer Review Committee |
| 1999-2007 | Legislative Key Contact Person Sarasota County Medical Society for Senator Lisa Carlton |
| 1999-2004 | Physician's Health Organization Sarasota Memorial Hospital Board of Directors |
| 1999-2003 | Physician's Health Organization Sarasota Memorial Hospital Utilization Review/Quality Issues Committee |
| 1999-2002 | Chief of Orthopedics Sarasota Memorial Hospital |
| 1999-2001 | Specialty Physician's Network Board of Directors |
| 1999-2001 | Pediatric Surgical Quality Improvement Team Sarasota Memorial Hospital |
| 1998-2001 | Resource Management Committee Doctors Hospital |

Societies:

American Medical Association
Florida Medical Association
Sarasota County Medical Society
Florida Physicians Association
American Academy of Orthopedic Surgeons

David A. Sugar, M.D.

Page Six

Research Experience:

Phase 3, Randomized, Double-Blind, Fixed Dose, Parallel-Group, Comparison of Controlled-Release XXX XXX (XXX) vs. Placebo in Subjects with Osteoarthritis

Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and the Safety of XXX on the Rate of Healing in Distal Radius Fractures. Sub-Investigator; David Klein, Principal Investigator. March, 2004 to September, 2004.

Phase IIb Dose-ranging trial of Oral Direct Factor Xa Inhibitor XXX in the Prevention of VTE in Patients Undergoing Total Knee Replacement, ODiXaKnee. Sub-Investigator; Walter K. Furman, Principal Investigator, February, 2004 to present.

Phase IV, flexibility in administration of XXX for prevention of symptomatic venous thromboembolism in orthopedic surgery. Sub-Investigator; Walter K. Furman, MD, Principal Investigator, August 2003 to January 2004.

RE-MOBILIZE. A Phase III Randomized, Parallel-Group, Double-Blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150mg Day 2 – Completion, and 110mg Day 1 Followed by 220mg Day 2 – Completion) of XXX Administered Orally (Capsules), Compared to XXX 30mg Twice a Day Subcutaneous for 12-15 Days, in Prevention of Venous Thromboembolism in Patients with Primary Elective Total Knee Replacement Surgery